

ASX ANNOUNCEMENT

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

TAVR PROGRESS CONTINUES WITH FILING OF NEW PROVISIONAL PATENTS

Admedus Limited (ASX:AHZ) today announced it has filed three new provisional patent applications in the United States as part of its Transcatheter Aortic Valve Replacement (TAVR) research and development project.

The three new provisional patent applications relate to 'additional embodiments of inventive valve replacement devices that reduce the 'French size' of the catheter required for delivery of the valve replacement device.'

In addition, some of the inventive concepts disclosed in the applications, provide improved reduction in regurgitation and additional means of control for a physician to recapture and reposition an (at least partially) deployed valve replacement device as needed during a procedure.

Since the project's inception in 2017, Admedus has submitted numerous provisional patent applications relating to the development of; a unique 3D single-piece moulded valve, sterile hydro-packaging, a reduced catheter 'French size', components that deliver enhanced valve placement and positioning, and a design element to reduce paravalvular leakage (PVL) which can lead to higher morbidity and poor health outcomes for patients.

Underpinned by its clinically-superior ADAPT® tissue technology, Admedus' TAVR aims to set a new benchmark in cardiovascular science and engineering and make an impact in the \$3.5B market (predicted to reach \$5B by 2020).

Admedus CEO Wayne Paterson welcomed the latest TAVR milestone,

"As I've said previously, with this project Admedus wants to set a new global standard in innovation and patient care, built on the absolute cutting-edge of medical science and engineering."

"With the design of each component, we are addressing vast areas of unmet need in durability, position and placement, cost-efficiency and improved patient outcomes - literally developing novel IP from one tip of the TAVR device to other."

"This is what makes the filing of these patent applications so critically important, we need to protect our significant investment and IP as competitors become increasingly aware of, and interested in, our progress. We're creating something special here, and the competition knows it."

"Although there is still a long road ahead, my confidence in the viability and potential of this project to attract a suitable commercial partner, continues to grow."

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore



“TAVR represents an enormous opportunity for Admedus to stamp its mark on the global medtech sector, beyond our already-proven superiority in tissue engineering science.”

Today's announcement follows the earlier notification that Admedus has entered into an agreement with a renowned European reference laboratory to commence the first TAVR animal trials in July.

ENDS

Background:

ADAPT®

ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Our clinically superior ADAPT® tissue products are the only one of their kind to have achieved nine years without calcification or degradation. With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

For more information, please contact:

Admedus Limited

Barbara Ferres

+61 7 3152 3216

communications@admedus.com

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore